YAP1 and ovarian carcinoma: For instance, overexpression of YAP1 could contribute to progression and poor prognosis of NSCLC [26], while knockdown of YAP1 sensitized ovarian cancer cells to cisplatin, erlotinib (EGFR Tyrosine kinase inhibitor) and S12 (survivin inhibitor) [27].